This collection examines corporate responsibilities in Swiss life sciences. Articles address directors’ duties within international groups, supply-chain due diligence and medical-device anti-kickback rules, distinguishing statutory obligations from the allocation of work, costs and liability within a group or contract.
These articles provide general information and are not legal advice.
A life-sciences group can fall under the EU due diligence directive as narrowed in 2026, Germany's supply chain act and the Swiss code of obligations; they differ on scope, depth, enforcement and liability. A broader draft Swiss act on sustainable corporate governance (NUFG) entered consultation in April 2026.
Swiss device-integrity rules await commencement, while transparency, insurance and bribery duties already apply to selected arrangements. Free equipment, royalties and training need separate analysis under the proposed rules and the existing US framework.
Swiss subsidiary directors retain duties despite group instructions and delegation. Company-law damages, unpaid contributions, liquidation taxes and criminal liability follow different rules, while parent indemnities and insurance raise separate questions about who funds a claim.
For advice on a particular matter, please get in touch.
Make an enquiry